Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.75 |
| ▸ | GAK | O14976 | 1/20 | 0.75 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.72 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.71 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14509726 | 0.89 | EGFR (0.75) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL2505296 | 0.89 | EGFR (0.77) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL2510931 | 0.89 | EGFR (0.75) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL233913 | 0.89 | EGFR (0.77) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL28407550 | 0.89 | EGFR (0.80) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL17083347 | 0.88 | EGFR (0.74) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL141514 | 0.88 | EGFR (0.73) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL9973598 | 0.88 | EGFR (0.73) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL14878664 | 0.88 | EGFR (0.79) | EGFRGAKERBB2ERBB4ERBB3 | |
| SCHEMBL12691367 | 0.88 | EGFR (0.76) | EGFRGAKERBB2ERBB4ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590966-A1 | QUINAZOLINE COMPOUNDS | Hutchison Medipharma Limited (CN) | 2013-05-15 | — | — | EP | claimed |
| WO-2012000356-A1 | QUINAZOLINE COMPOUNDS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-01-05 | — | — | WO | claimed |
| EP-1854789-B1 | QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2013-10-09 | — | — | EP | disclosed |
| EP-2590966-A1 | QUINAZOLINE COMPOUNDS | Hutchison Medipharma Limited (CN) | 2013-05-15 | — | — | EP | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| WO-2012000356-A1 | QUINAZOLINE COMPOUNDS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-01-05 | — | — | WO | disclosed |
| US-20110212475-A1 | Fluorescently Or Spin-Labeled Kinases For Rapid Screening And Identification Of Novel Kinase Inhibitor Scaffolds | MAX-PLANCK GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212475-A1 | Fluorescently Or Spin-Labeled Kinases For Rapid Screening And Identification Of Novel Kinase Inhibitor Scaffolds | MAX-PLANCK GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1854789-A1 | QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | EGFR 2/4885GAK 340/4885ERBB2 1/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | EGFR 2/4885GAK 340/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.